Ionis Pharmaceuticals (NASDAQ: IONS) experienced a sharp decline on Thursday, with shares falling 23.2% to $64.83, as the company and its partner AstraZeneca (NASDAQ: AZN) reported that the experimental heart drug Wainua failed to meet its primary endpoint in a pivotal late-stage trial. The drop erased approximately $3.2 billion in market capitalization, far outpacing the broader biotech sector, as the SPDR S&P Biotech ETF (NYSEARCA: XBI) rose 0.7% and the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) gained 0.2% during the same period.
The CARDIO-TTRansform Phase 3 study evaluated Wainua in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a serious condition where misfolded transthyretin protein accumulates in the heart, impairing its ability to pump blood. The trial failed to achieve its primary composite endpoint, which combined cardiovascular death and recurrent cardiovascular events tracked over 140 weeks. Notably, patients already on stabilizer drugs, such as Pfizer's Vyndaqel, did not derive additional benefit from Wainua. In a monotherapy subgroup, the hazard ratio was 0.71, indicating a favorable trend for treated patients versus placebo, but the result only reached nominal significance and did not alter the overall trial outcome.
Market Impact and Competitive Landscape
The news sent ripples across the sector. AstraZeneca's ADR shares fell 5.5% to $178.80, while BridgeBio Pharma (NASDAQ: BBIO) surged 17.4% to $91.94, as investors viewed the setback as a competitive opportunity for its approved ATTR-CM drug. Alnylam Pharmaceuticals (NASDAQ: ALNY) initially popped on read-throughs but closed down 0.3% at $322.55. Pfizer (NYSE: PFE) edged up 0.6% to $24.19, as its stabilizer franchise appeared more resilient. Analysts had previously forecast up to $2 billion in peak sales for Wainua in ATTR-CM, according to Reuters.
BofA analyst Sachin Jain described the data as a surprise, while JM Finn's Lucy Coutts suggested the result could temper expectations for AstraZeneca. The competitive angle is nuanced: Wainua and Alnylam's Amvuttra both lower transthyretin protein, while Pfizer's Vyndaqel stabilizes the protein already in circulation. With the trial failing to show added benefit on top of stabilizers, payers may question the rationale for combination therapy.
Analyst Reactions and Price Target Changes
Several analysts adjusted their price targets for Ionis following the miss. Jefferies lowered its target to $90 from $113, maintaining a Buy rating, with analyst Akash Tewari attributing the failure to tafamidis overperformance. TD Cowen cut its target to $94 from $108, keeping a Buy, noting that the monotherapy data appeared consistent with Amvuttra's HELIOS-B results. Oppenheimer reduced its target to $92 from $110, with an Outperform rating, stating the miss narrows near-term gains but the pipeline remains viable.
Financial Impact and Shift in Focus
The valuation impact outweighs the near-term revenue effect. Wainua generated $51 million in global first-quarter sales for AstraZeneca, translating to $11 million in royalty revenue for Ionis. Ionis reported total Q1 revenue of $246 million and held $1.9 billion in cash and short-term investments as of March 31. In April, the company raised its 2026 revenue guidance to $875 million-$900 million.
With Wainua's cardiomyopathy prospects dimmed, attention now pivots to TRYNGOLZA, Ionis' first independent commercial launch in a common disease. The FDA approved TRYNGOLZA on June 24 for reducing triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia, and the drug is expected to be available in the U.S. this month. CEO Brett Monia emphasized the company's focus on its wholly owned pipeline, while primary investigator Mathew Maurer of Columbia University noted that full data will be presented at the European Society of Cardiology Congress in August.
Risks and Outlook
Downside risks remain. If regulators view the monotherapy subgroup as insufficient or if payers see limited use for Wainua outside stabilizers, the cardiomyopathy push could be delayed or abandoned. Ionis would then rely on TRYNGOLZA sales, DAWNZERA growth, and other pipeline prospects to support a stock that, even after Thursday's decline, is priced on future launches rather than current profits.
